EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical impact of BioFire Blood Culture Identification 2 implementation in patients with Staphylococcus bacteremia

Colin H Duell iD, Tyler Ackley iD, Kristin E Linder, Joseph L Kuti iD, Alivia Castle, Rosanna Li

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.01093-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Colin H Duell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Bacteremia, Staphylococcal Infections, Blood Culture, Staphylococcus. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The BioFire Blood Culture Identification 2 (BCID2) PCR panel allows for rapid identification of blood pathogens, including Staphylococci other than Staphylococcus aureus (SOSA) and methicillin-susceptible S. aureus (MSSA). The objective of this study was to evaluate how BCID2 implementation impacted duration of vancomycin therapy, clinical outcomes, and rate of pharmacist intervention. This was a multi-center, retrospective study of adult patients admitted with MSSA or SOSA-positive blood cultures. The primary endpoint, days of vancomycin therapy, was compared between the pre- and post-BCID2 periods. Secondary endpoints included duration of MSSA bacteremia, hospital mortality, and pharmacist interventions. Of the 617 patients included in the primary analysis, MSSA bloodstream infection (BSI) accounted for 37.0% (110/297) and 31.6% (101/320) of the pre- and post-BCID2 group, respectively ( P = 0.178). The median duration of vancomycin was 1.3 and 0.3 days in the pre- and post-BCID2 groups, respectively (absolute difference, 1.0 days; P < 0.001). The duration of MSSA BSI was 3.1 and 2.4 days in the pre- and post-BCID2 group, respectively (absolute difference, 0.7 days; P = 0.096). Hospital mortality was not different between periods (7.1% [21/297] vs 10.6% [34/320], P = 0.16). Pharmacists successfully intervened to reduce vancomycin duration in 7.1% (21/297) and 16.3% (52/320) of patients in the pre- and post-BCID2 group, respectively ( P < 0.001). BCID2 implementation shortened the duration of vancomycin in patients with MSSA or SOSA bacteremia. These data support BCID2 as a critical tool to improve appropriate antibiotic selection and shorten the time to safer and more effective treatment for patients with SOSA and MSSA bacteremia. IMPORTANCE PCR-based blood culture testing with concurrent antimicrobial stewardship program review continues to facilitate the initiation of pathogen-targeted antimicrobials in a shorter amount of time compared to traditional methods. The initiation of pathogen-targeted antimicrobials compared to non-pathogen-targeted antimicrobials has been shown to improve clinical outcomes in bloodstream infections caused by specific pathogens (e.g., methicillin-susceptible Staphylococcus aureus [MSSA]). Additionally, the adverse effects of vancomycin may be decreased with a shorter duration in blood culture contamination caused by coagulase-negative Staphylococcus species. This retrospective study evaluated the amount of time BCID2 results with pharmacist review and intervention reduced time to pathogen-targeted antimicrobials in MSSA, and time to discontinuation in blood culture contamination by coagulase-negative Staphylococcus species. Secondary outcomes mainly evaluated the clinical effects of these interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaStaphylococcal InfectionsBlood CultureStaphylococcusHumansRetrospective StudiesFemaleMaleAnti-Bacterial AgentsMiddle AgedAgedVancomycinAged, 80 and overAdultPolymerase Chain ReactionStaphylococcus aureus

Stichwörter der Autor:innen

antimicrobial stewardshipbacteremiabloodstream infectionsrapid diagnostic tests

Substanzen

Anti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • Department of Pharmacy Services, Hartford Hospital, Hartford, Connecticut, USA.
  • Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • School of Pharmacy and Physician Assistant Studies, The University of Saint Joseph, West Hartford, Connecticut, USA.
  • Department of Pharmacy Services, Hartford Healthcare, Hartford, Connecticut, USA.

ORCID-Profile: Colin H Duell, Tyler Ackley, Joseph L Kuti

Zitieren

APA

Duell, C. H., Ackley, T., Linder, K. E., Kuti, J. L., Castle, A., & Li, R. (2026). Clinical impact of BioFire Blood Culture Identification 2 implementation in patients with Staphylococcus bacteremia. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01093-25

Vancouver

Duell CH, Ackley T, Linder KE, Kuti JL, Castle A, Li R. Clinical impact of BioFire Blood Culture Identification 2 implementation in patients with Staphylococcus bacteremia. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01093-25

BibTeX
@article{Duell2026,
  author = {Duell, Colin H and Ackley, Tyler and Linder, Kristin E and Kuti, Joseph L and Castle, Alivia and Li, Rosanna},
  title = {Clinical impact of BioFire Blood Culture Identification 2 implementation in patients with Staphylococcus bacteremia},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.01093-25}
}
Kostenlos starten →